BioHarvest Sciences (NASDAQ: BHST) secures $1.4M AI plant-cell research grant

Rhea-AI Filing Summary

BioHarvest Sciences Inc. reports that the Israel Innovation Authority has approved a 4.33 million NIS (approximately USD $1.4 million) non-dilutive grant to fund an AI-driven plant-cell synthesis research program. The funding will integrate data science, machine learning, computer vision and high-throughput digital sensing into its biological development workflows.

The project aims to replace trial-and-error plant cell culture with a predictive, data-focused platform that maximizes active metabolite yields for CDMO customers and partners. The grant is structured as a zero-interest loan, repayable only from future revenues generated by the funded project, and involves no equity or equity-linked issuance. It is the second Israel Innovation Authority grant this year, complementing a prior award focused on automating and scaling manufacturing operations.

Key Figures

IIA grant size: 4.33 million NIS Grant size (USD equivalent): USD $1.4 million Interest rate on grant: 0% +1 more

4 metrics

IIA grant size 4.33 million NIS Non-dilutive grant approved by the Israel Innovation Authority for AI-driven plant-cell R&D

Grant size (USD equivalent) USD $1.4 million Approximate U.S. dollar value of the 4.33 million NIS Israel Innovation Authority grant

Interest rate on grant 0% Grant structured as a non-dilutive, zero-interest loan repayable from future project revenues

Number of IIA grants in 2026 2 Second Israel Innovation Authority grant received by BioHarvest in the same year

Key Terms

Botanical Synthesis, CDMO, non-dilutive, bioinformatics, +2 more

6 terms

Botanical Synthesis technical

"a leader in Botanical Synthesis technology and sustainable plant-based molecule development"

Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.

CDMO financial

"for the benefit of BioHarvest’s CDMO customers and partners"

A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.

non-dilutive financial

"This non-dilutive funding will support a new research initiative"

Non-dilutive describes funding or income that does not reduce existing shareholders’ ownership percentage. It matters to investors because it lets a company raise money or generate value—through grants, loans, licensing deals, or revenue—without issuing extra shares, so each existing share keeps the same claim on profits and control; think of adding toppings to a cake without cutting it into more slices.

bioinformatics technical

"by combining bioinformatics, chemo-informatics and artificial intelligence"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

high-throughput digital sensing technical

"integrating advanced data science, machine learning, computer vision and high-throughput digital sensing"

Israel Innovation Authority regulatory

"the Israel Innovation Authority (IIA) has approved a 4.33 million NIS grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/15/2026 - 03:25 PM Accepted by SEC EDGAR 07/15/2026 - 03:24 PM Learn about SEC filing dates

FAQ

What grant did BioHarvest Sciences (BHST) receive from the Israel Innovation Authority?

BioHarvest Sciences received a 4.33 million NIS (about USD $1.4 million) non-dilutive grant from the Israel Innovation Authority. The zero-interest funding supports an AI-driven plant-cell synthesis research initiative aimed at accelerating and optimizing development of complex plant-based compounds.

How will BioHarvest Sciences (BHST) use the new Israel Innovation Authority grant?

The grant will fund integration of data science, machine learning, computer vision and digital sensing into BioHarvest’s plant cell culture workflows. This aims to build a predictive platform that improves success rates and maximizes active metabolite yields for CDMO customers and partners.

Is the BioHarvest Sciences (BHST) Israel Innovation Authority grant dilutive to shareholders?

The grant is described as non-dilutive and structured as a zero-interest loan. Repayment is contingent on predefined commercial milestones and expected to come only from future revenues generated by the funded project, with no equity or equity-linked securities issued.

What makes this new research initiative important for BioHarvest Sciences (BHST)?

The initiative shifts plant cell culture from empirical trial-and-error to a predictive, data-driven framework. By combining bioinformatics, chemo-informatics and artificial intelligence, BioHarvest plans to forecast propagation success and significantly increase bioactive compound yields across diverse plant species.

How does this BioHarvest Sciences (BHST) grant relate to its earlier 2026 Israel Innovation Authority support?

This is BioHarvest’s second Israel Innovation Authority grant in 2026, focused on early-stage R&D and predictive AI. The earlier grant targeted scaling the manufacturing facility with industrial automation and machine learning, together creating a technology upgrade from lab discovery to commercial production.

What are the repayment terms of the BioHarvest Sciences (BHST) Israel Innovation Authority grant?

The grant is provided as a zero-interest loan with repayment tied to achieving predefined commercial milestones. Payments are expected to come solely from future revenues of the funded project, aligning obligations with successful commercialization rather than current cash resources.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated July 15, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: July 15, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

 

BioHarvest Awarded $1.4M Grant from the Israel Innovation Authority to Pioneer AI-Driven Plant-Cell Synthesis

Grant to partially fund research that will enable faster development, with a higher probability of success, of new plant-based compounds (precision botanics) for the benefit of BioHarvest’s CDMO customers and partners

Vancouver, British Columbia and Rehovot, Israel – BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that the Israel Innovation Authority (IIA) has approved a 4.33 million NIS (approximately USD $1.4 million) grant. This non-dilutive funding will support a new research initiative at BioHarvest integrating advanced data science, machine learning, computer vision and high-throughput digital sensing directly into BioHarvest’s biological development workflows, thereby accelerating its plant cell culture programs.

BioHarvest’s new approved research initiative focuses on moving plant cell culture from traditional empirical trial-and-error methods to a highly predictable, data-driven optimization framework. Specifically, by combining bioinformatics, chemo-informatics and artificial intelligence, the platform will systematically predict the success of plant cell propagation and dramatically maximize active metabolite yields.

Dr. Zaki Rakib, Chairman and Chief Executive Officer of BioHarvest, commented, “We are extremely thankful for the additional support from the IIA. This grant, the second we have received from IIA, strengthens the Company’s financial position by providing non-dilutive capital support as we additionally implement a more efficient, smarter means for our biological development workflows.”

Specifically, the program will accelerate the development of BioHarvest’s advanced computational discovery engine. This platform integrates proprietary predictive machine learning models with real-time digital sensing to rapidly identify optimal pathways and maximize bioactive yields across diverse plant species. Supported by secure, domain-specific scientific knowledge bases, these new capabilities will streamline early-stage R&D, transforming how complex plant-based compounds are forecasted, monitored, and scaled.

This marks the second grant BioHarvest has received from the Israel Innovation Authority this year. While the first grant was dedicated to scaling the manufacturing facility by integrating industrial automation and machine learning on the factory floor, this second grant is strictly focused on transforming the early-stage R&D pipeline through predictive AI. Together, these two distinct yet highly complementary initiatives fuel a technological transformation across the company—bridging the gap between intelligent, data-driven laboratory discovery and high-volume, autonomous commercial production.

The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial

milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.

About the Israeli Innovation Authority (IIA)

The Israeli Innovation Authority is a government entity dedicated to fostering Israel’s innovation ecosystem by supporting companies across all stages of technology development, from early research through industrial deployment. For more information, visit https://innovationisrael.org.il/en/.

About BioHarvest

BioHarvest (NASDAQ: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products based on its botanical synthesis technology. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management’s current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. The project being funded is a research project and there is no assurance that future revenues will be generated from the project, and successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured. Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company’s SEC filings, available at http://www.sec.gov.

BioHarvest Company Contact:

Dave Ryan, VP Investor Relations

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

2

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED JULY 15, 2026 9.5 KB